IMPACT-MACS: Adrenalectomía frente a Semaglutida para Resultados Metabólicos en la Secreción Cortisol Autónoma Leve (IMPACT-MACS)
Estudio IMPACT-MACS: Investigación de los Mecanismos, Fisiopatología y Tratamiento Cardiometabólico en la Secreción Autónoma Leve de Cortisol
The goal of this study is to learn how two treatments-adrenalectomy (surgical removal of an adrenal gland) and semaglutide (a medication used for weight management)-affect insulin resistance and cortisol regulation in adults with mild autonomous cortisol secretion (MACS). The study will also learn how these treatments impact body composition, blood pressure, cholesterol, inflammation, muscle strength, and quality of life.
The main questions the study aims to answer are:
- Does adrenalectomy or semaglutide improve insulin resistance more in people with MACS?
- How do these treatments change cortisol patterns and other cardiometabolic risk factors?
- Do people with MACS respond differently to semaglutide compared to matched adults without MACS?
- Among participants who enter the optional extension phase, are treatment-related changes maintained or further modified with longer-term treatment and follow-up?
Participants will:
- Receive either adrenalectomy or semaglutide if they have MACS, or semaglutide if they are matched controls
- Complete clinic visits and phone visits
- Undergo metabolic testing such as blood tests, urine steroid profiling, body composition scans, blood pressure monitoring, muscle strength testing, and questionnaires about health and well-being
- If eligible, have the option to participate in an extension phase with continued treatment and follow-up through approximately 12 months
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
This single-center, prospective, interventional study evaluates metabolic responses to surgical versus medical treatment in adults with mild autonomous cortisol secretion (MACS). The study includes:
- a randomized controlled trial comparing adrenalectomy to semaglutide in MACS, and
- a parallel matched case-control comparison evaluating semaglutide effects in MACS versus matched controls without adrenal tumors.
The primary objective is to compare changes in insulin sensitivity measured by hyperinsulinemic-euglycemic clamp (M-value) from baseline to week 26. Secondary outcomes include cortisol dynamics, steroid profiling, cardiometabolic biomarkers, body composition, blood pressure, muscle strength, and patient-reported quality of life.
Semaglutide is administered within its FDA-approved indication for weight management; adrenalectomy is standard of care. No IND is required.
Participants who complete the initial 26-week study period and meet applicable eligibility criteria may elect to participate in an optional extension phase through approximately Week 52. During the extension phase, participants continue study follow-up and the intervention specified by the protocol, with additional assessments to evaluate longer-term changes in metabolic, hormonal, anthropometric, and cardiometabolic outcomes. Participation in the extension phase is voluntary and is not required for completion of the initial study period. The original primary outcome remains the change in insulin sensitivity from baseline to Week 26; assessments during the extension phase evaluate longer-term treatment effects and durability of response.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 4
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Oksana Hamidi, DO, MSCS
- Número de teléfono: 214-645-6397
- Correo electrónico: oksana.hamidi@utsouthwestern.edu
Ubicaciones de estudio
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75390
- Reclutamiento
- University of Texas Southwestern Medical Center
-
Contacto:
- Correo electrónico: oksana.hamidi@utsouthwestern.edu
-
Investigador principal:
- Oksana Hamidi, DO, MSCS
-
Contacto:
- Oksana Hamidi, DO, MSCS
- Número de teléfono: 2146456397
- Correo electrónico: oksana.hamidi@utsouthwestern.edu
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Adults ≥18 years
- MACS groups: adrenal adenoma + DST cortisol >1.8 µg/dL + no overt Cushing + eligible for adrenalectomy
- Willingness to postpone surgery 6 months if randomized
- Controls: no adrenal abnormalities + normal DST + BMI ≥27 + ≥2 cardiometabolic conditions
- Stable medication doses for ≥4 weeks
- Negative pregnancy test if applicable
Exclusion Criteria:
- Prior GLP-1 RA within 90 days
- Weight change >5 kg in past 90 days
- Prior obesity/diabetes surgery
- Type 1 diabetes or other diabetes types
- Severe organ disease
- Recent pancreatitis
- Pregnancy, breastfeeding
- Contraindication to semaglutide
- Contraindication to surgery delay
- Chronic glucocorticoid use
Optional Extension Phase Eligibility:
Participants who complete the Core Study Period may participate in the Optional Extension Phase if they:
- Successfully complete all Week 26 (Visit 8) assessments and procedures;
- Remain compliant with study requirements;
- Are considered by the Investigator to be appropriate for safe continued participation; and
- Confirm their willingness to participate in the Optional Extension Phase.
For matched controls, the corresponding matched index participant must also elect to participate in the Optional Extension Phase and remain eligible for continued study participation.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Comparador activo: Arm 1: Adrenalectomy (MACS)
Adults with mild autonomous cortisol secretion (MACS) who are clinically eligible for adrenalectomy undergo unilateral adrenalectomy as part of standard clinical care. Participants complete protocol-specified metabolic, hormonal, cardiometabolic, body composition, physical function, and patient-reported outcome assessments through Week 26. Eligible participants may elect to participate in the Optional Extension Phase, with continued follow-up and repeat outcome assessments through Month 12. |
Surgical removal of one adrenal gland performed by an endocrine surgeon following institutional standard-of-care practices. Includes postoperative monitoring for adrenal insufficiency and routine clinical follow-up. |
|
Comparador activo: Arm 2: Semaglutide (MACS)
Adults with MACS receive semaglutide during the initial 26-week treatment period. Eligible participants who elect to participate in the optional extension phase continue semaglutide treatment and protocol-specified follow-up through Month 12. |
Once-weekly subcutaneous semaglutide administered according to FDA-approved titration for chronic weight management (0.25 mg to 2.4 mg weekly as tolerated). Participants receive training on injection technique, dose escalation, and safety monitoring. |
|
Comparador activo: Arm 3: Semaglutide (Matched Controls)
Matched adults without adrenal tumors receive semaglutide using the same dosing approach as semaglutide-treated participants with MACS. This arm allows comparison of semaglutide responses between individuals with and without MACS. Eligible matched controls may participate in the Optional Extension Phase through Month 12 if their corresponding matched index participant also elects to participate and both remain eligible for continued study participation. |
Once-weekly subcutaneous semaglutide administered according to FDA-approved titration for chronic weight management (0.25 mg to 2.4 mg weekly as tolerated). Participants receive training on injection technique, dose escalation, and safety monitoring. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Insulin Sensitivity (M-value), mg/kg/min
Periodo de tiempo: Baseline to Week 26
|
Hyperinsulinemic-euglycemic clamp |
Baseline to Week 26
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in fasting plasma glucose, mg/dL
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
Baseline to Week 26; Baseline → Month 12
|
|
|
Change in hemoglobin A1C, %
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
fasting blood test |
Baseline to Week 26; Baseline → Month 12
|
|
Change in fasting insulin, µU/mL
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
Fasting blood test |
Baseline to Week 26; Baseline → Month 12
|
|
Change in glucagon, pg/mL
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
Fasting blood test |
Baseline to Week 26; Baseline → Month 12
|
|
Change in c-peptide, nmol/L
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
Fasting blood test |
Baseline to Week 26; Baseline → Month 12
|
|
Change in IGF-1, ng/mL
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
Fasting blood glucose |
Baseline to Week 26; Baseline → Month 12
|
|
Change in IGF-II, ng/mL
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
Fasting blood test |
Baseline to Week 26; Baseline → Month 12
|
|
Change in IGFBP-1, ng/mL
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
Fasting blood test |
Baseline to Week 26; Baseline → Month 12
|
|
Change in leptin, ng/mL
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
Fasting blood glucose |
Baseline to Week 26; Baseline → Month 12
|
|
Change in adiponectin, μg/mL
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
Fasting blood test |
Baseline to Week 26; Baseline → Month 12
|
|
% of patients with normal dexamethasone suppression test, %
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
1-mg dexamethasone suppression test |
Baseline to Week 26; Baseline → Month 12
|
|
Change in steroid profile, ng/24h
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
25-steroid profiling in the 24-hour urine, reported as aggregate |
Baseline to Week 26; Baseline → Month 12
|
|
Mean change in systolic BP, mmHg
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
24-hour Ambulatory BP |
Baseline to Week 26; Baseline → Month 12
|
|
Mean change in diastolic BP, mmHg
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
24-hour Ambulatory BP |
Baseline to Week 26; Baseline → Month 12
|
|
Change in cholesterol, mg/dL
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
Fasting blood test |
Baseline to Week 26; Baseline → Month 12
|
|
Change in Free Fatty Acids, mmol/L
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
Fasting blood test |
Baseline to Week 26; Baseline → Month 12
|
|
Change in C-reactive protein, pg/mL
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
Fasting blood test |
Baseline to Week 26; Baseline → Month 12
|
|
Change in TNF-alpha, pg/mL
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
Fasting blood glucose |
Baseline to Week 26; Baseline → Month 12
|
|
Change in Interleukin-1, pg/mL
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
Fasting blood test |
Baseline to Week 26; Baseline → Month 12
|
|
Change in Interleukin-6, pg/mL
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
Fasting blood test |
Baseline to Week 26; Baseline → Month 12
|
|
Change in body weight, kg
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
electronic scale |
Baseline to Week 26; Baseline → Month 12
|
|
Change in BMI, kg/m2
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
calculated from weight and height |
Baseline to Week 26; Baseline → Month 12
|
|
Change in waist circumference, cm
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
Tape measure |
Baseline to Week 26; Baseline → Month 12
|
|
Change in fat area, cm2
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
Limited unenhanced CT |
Baseline to Week 26; Baseline → Month 12
|
|
Change in muscle area, cm2
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
Limited unenhanced CT |
Baseline to Week 26; Baseline → Month 12
|
|
Change in bone mineral density, mg/cm³
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
Limited unenhanced CT |
Baseline to Week 26; Baseline → Month 12
|
|
Change in chair rise test, stands/30s
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
Time test, number of stands from chair in 30 seconds |
Baseline to Week 26; Baseline → Month 12
|
|
Change in Hand Grip Strength, kg
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
Dynamometer |
Baseline to Week 26; Baseline → Month 12
|
|
Change in overall quality of life, score
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
PROMIS Global Health Questionnaire, domain-specific scales; The Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health v1.2 Questionnaire assesses overall health-related quality of life across multiple domains, including physical health, mental health, social functioning, fatigue, and general well-being. It yields two standardized T-score summary measures (Global Physical Health and Global Mental Health). Score Range: T-scores typically range from 20 to 80. Interpretation: Higher T-scores indicate better health-related quality of life. Assessment Method: Self-report questionnaire; estimated completion time 2-5 minutes. |
Baseline to Week 26; Baseline → Month 12
|
|
Change in disease-specific QoL, score
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
Cushing Quality of Life Questionnaire (CushingQoL) Description: The Cushing Quality of Life Questionnaire (CushingQoL) is a disease-specific tool assessing health-related quality of life in individuals with hypercortisolism. It contains 12 items scored on a 5-point Likert scale. Score Range: 12 (minimum) to 60 (maximum). Interpretation: Higher scores indicate better quality of life; lower scores indicate poorer quality of life. Domains: Sleep disturbances, mood, physical appearance, social interaction, health concerns. Assessment Method: Self-administered; estimated completion time ~5 minutes. |
Baseline to Week 26; Baseline → Month 12
|
|
Change in mood, score
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
PROMIS Depression Short Form & PROMIS Anxiety Short Form Description: The PROMIS Depression Short Form and PROMIS Anxiety Short Form measure depressive and anxiety symptoms over the past seven days, assessing emotional distress, negative affect, and somatic symptoms. Responses are on a 5-point Likert scale ("Never" to "Always"), converted to standardized T-scores. Score Range: T-scores typically range from 20 to 80. Interpretation: Higher scores indicate worse depressive or anxiety symptoms. Assessment Method: Self-report questionnaires; estimated completion time 2-4 minutes each. |
Baseline to Week 26; Baseline → Month 12
|
|
Change in cognition, seconds
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
Trail Making Test - Part A and Part B (TMT-A and TMT-B) Description: The Trail Making Test Parts A and B assess visual attention, processing speed, cognitive flexibility, and executive function. Part A requires sequential connection of numbers; Part B requires alternating between numbers and letters. Score Range: 0 to 300 seconds (maximum test time). Interpretation: Higher (longer) completion times indicate worse cognitive performance. Assessment Method: Performance-based timed test administered by study personnel; expected duration ~5 minutes. |
Baseline to Week 26; Baseline → Month 12
|
|
Change in sleep, score
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
PROMIS Sleep Disturbance Short Form Description: The PROMIS Sleep Disturbance Short Form evaluates sleep quality, difficulty initiating and maintaining sleep, and overall sleep problems over the past seven days. Scores are converted into standardized T-scores. Score Range: T-scores typically range from 20 to 80. Interpretation: Higher scores indicate worse sleep disturbance. Assessment Method: Self-administered; estimated completion time 2-4 minutes. |
Baseline to Week 26; Baseline → Month 12
|
|
Change in frailty, score
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
FRAIL Scale (Fatigue, Resistance, Ambulation, Illnesses, Loss of Weight) Description: The FRAIL Scale is a validated screening instrument assessing functional decline and physiological frailty. It consists of five yes/no items: fatigue, resistance, ambulation, illnesses, and weight loss. Score Range: 0 (minimum) to 5 (maximum). Interpretation: Higher scores indicate greater frailty. Frailty Categories: 0: Robust 1-2: Pre-frail 3-5: Frail Assessment Method: Administered by study personnel; duration ~1 minute. |
Baseline to Week 26; Baseline → Month 12
|
|
Change in eating behavior, score
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
Eating Behavior and Appetite Questionnaire (EBAQ) Description: The Eating Behavior and Appetite Questionnaire (EBAQ) evaluates hunger, satiety, food cravings, and changes in appetite and eating behavior. It generates domain-specific and total scores. Score Range: Varies by version; treated as continuous scores with defined minimum and maximum values per subscale. Interpretation: Higher scores indicate greater appetite or more pronounced eating-behavior disturbances. Assessment Method: Self-administered; estimated completion time 3-5 minutes. |
Baseline to Week 26; Baseline → Month 12
|
|
Adverse Events and Serious Adverse Events
Periodo de tiempo: From assigned intervention through 4 weeks after the end of treatment, up to approximately Month 13 for participants entering the Optional Extension Phase.
|
AEs, SAEs |
From assigned intervention through 4 weeks after the end of treatment, up to approximately Month 13 for participants entering the Optional Extension Phase.
|
|
Change in Insulin Sensitivity (M-value) at Month 12
Periodo de tiempo: Time Frame: Baseline to Month 12
|
Hyperinsulinemic-euglycemic clamp |
Time Frame: Baseline to Month 12
|
|
Change in post-DST cortisol as a continuous variable
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
1-mg dexamethasone suppression test |
Baseline to Week 26; Baseline → Month 12
|
|
Change in ACTH level
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
Blood test |
Baseline to Week 26; Baseline → Month 12
|
|
DHEA-S
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
Blood test |
Baseline to Week 26; Baseline → Month 12
|
|
HDL
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
Blood test |
Baseline to Week 26; Baseline → Month 12
|
|
LDL
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
Blood test |
Baseline to Week 26; Baseline → Month 12
|
|
triglycerides
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
Blood test |
Baseline to Week 26; Baseline → Month 12
|
|
Apo B
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
Blood test |
Baseline to Week 26; Baseline → Month 12
|
|
Lp(a)
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
Blood test |
Baseline to Week 26; Baseline → Month 12
|
|
HDL function
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
Blood test |
Baseline to Week 26; Baseline → Month 12
|
|
cholesterol efflux capacity
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
Blood test |
Baseline to Week 26; Baseline → Month 12
|
|
Change in total fat area
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
Body composition |
Baseline to Week 26; Baseline → Month 12
|
|
Change in visceral fat area
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
Body composition |
Baseline to Week 26; Baseline → Month 12
|
|
Change in subcutaneous fat area
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
Body composition |
Baseline to Week 26; Baseline → Month 12
|
|
Change in muscle area
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
Body composition |
Baseline to Week 26; Baseline → Month 12
|
|
Change in muscle:fat ratio
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
Body composition |
Baseline to Week 26; Baseline → Month 12
|
|
Change in liver fat
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
Body composition |
Baseline to Week 26; Baseline → Month 12
|
|
Change in pancreatic fat
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
Body composition |
Baseline to Week 26; Baseline → Month 12
|
|
Change in pancreatic volume
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
Body composition |
Baseline to Week 26; Baseline → Month 12
|
|
Change in adrenal nodule size
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
|
CT abdomen |
Baseline to Week 26; Baseline → Month 12
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Publicaciones y enlaces útiles
Publicaciones Generales
- Ebbehoj A, Li D, Kaur RJ, Zhang C, Singh S, Li T, Atkinson E, Achenbach S, Khosla S, Arlt W, Young WF, Rocca WA, Bancos I. Epidemiology of adrenal tumours in Olmsted County, Minnesota, USA: a population-based cohort study. Lancet Diabetes Endocrinol. 2020 Nov;8(11):894-902. doi: 10.1016/S2213-8587(20)30314-4.
- Yozamp N, Vaidya A. Assessment of mild autonomous cortisol secretion among incidentally discovered adrenal masses. Best Pract Res Clin Endocrinol Metab. 2021 Jan;35(1):101491. doi: 10.1016/j.beem.2021.101491. Epub 2021 Feb 6.
- Bancos I, Prete A. Approach to the Patient With Adrenal Incidentaloma. J Clin Endocrinol Metab. 2021 Oct 21;106(11):3331-3353. doi: 10.1210/clinem/dgab512.
- Prete A, Subramanian A, Bancos I, Chortis V, Tsagarakis S, Lang K, Macech M, Delivanis DA, Pupovac ID, Reimondo G, Marina LV, Deutschbein T, Balomenaki M, O'Reilly MW, Gilligan LC, Jenkinson C, Bednarczuk T, Zhang CD, Dusek T, Diamantopoulos A, Asia M, Kondracka A, Li D, Masjkur JR, Quinkler M, Ueland GA, Dennedy MC, Beuschlein F, Tabarin A, Fassnacht M, Ivovic M, Terzolo M, Kastelan D, Young WF Jr, Manolopoulos KN, Ambroziak U, Vassiliadi DA, Taylor AE, Sitch AJ, Nirantharakumar K, Arlt W; ENSAT EURINE-ACT Investigators*; ENSAT EURINE-ACT Investigators. Cardiometabolic Disease Burden and Steroid Excretion in Benign Adrenal Tumors : A Cross-Sectional Multicenter Study. Ann Intern Med. 2022 Mar;175(3):325-334. doi: 10.7326/M21-1737. Epub 2022 Jan 4.
- Fassnacht M, Tsagarakis S, Terzolo M, Tabarin A, Sahdev A, Newell-Price J, Pelsma I, Marina L, Lorenz K, Bancos I, Arlt W, Dekkers OM. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2023 Jul 20;189(1):G1-G42. doi: 10.1093/ejendo/lvad066.
- Kolanska K, Owecki M, Nikisch E, Sowinski J. High prevalence of obesity in patients with non-functioning adrenal incidentalomas. Neuro Endocrinol Lett. 2010;31(3):418-22.
- Reimondo G, Castellano E, Grosso M, Priotto R, Puglisi S, Pia A, Pellegrino M, Borretta G, Terzolo M. Adrenal Incidentalomas are Tied to Increased Risk of Diabetes: Findings from a Prospective Study. J Clin Endocrinol Metab. 2020 Apr 1;105(4):dgz284. doi: 10.1210/clinem/dgz284.
- Bovio S, Cataldi A, Reimondo G, Sperone P, Novello S, Berruti A, Borasio P, Fava C, Dogliotti L, Scagliotti GV, Angeli A, Terzolo M. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrinol Invest. 2006 Apr;29(4):298-302. doi: 10.1007/BF03344099.
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
- ensayo controlado aleatorizado
- Resistencia a la insulina
- Semaglutida
- Pérdida de peso
- Composición corporal
- riesgo cardiometabólico
- Grasa visceral
- Hipercortisolismo
- Agonista del receptor de GLP-1
- MACS
- Adenoma suprarrenal
- Suprarrenalectomía
- Incidentaloma suprarrenal
- Secreción Autónoma Leve de Cortisol
- Cushing subclínico
- Desregulación del cortisol
- Pinzamiento hiperinsulinémico-euglucémico
- Dinámica del cortisol
Términos MeSH relevantes adicionales
- Enfermedades del sistema endocrino
- Neoplasias
- Enfermedades metabólicas
- Peso corporal
- Cambios en el peso corporal
- Trastornos del metabolismo de la glucosa
- Hiperinsulinismo
- Síndromes paraneoplásicos
- Enfermedades de las glándulas suprarrenales
- Hiperfunción adrenocortical
- Síndromes endocrinos paraneoplásicos
- Condiciones Patológicas, Signos y Síntomas
- Enfermedades Nutricionales y Metabólicas
- Signos y síntomas
- Pérdida de peso
- Resistencia a la insulina
- Síndrome de Cushing
- Síndrome de ACTH, Ectópico
- Incidentaloma suprarrenal
Otros números de identificación del estudio
Otros números de identificación del estudio
- STU20251717
- 1K23DK142038-01A1 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
De-identified individual participant data (IPD) from the IMPACT-MACS study will be shared in accordance with NIH Data Management and Sharing Policy. Shared IPD will include primary and secondary outcome data such as insulin sensitivity (M-value), hormonal and cardiometabolic biomarkers, body composition measures, ambulatory blood pressure data, physical function tests, patient-reported outcomes, and adverse events. No genetic data will be shared. IPD will become available at the time of primary publication or by the end of the award period, expected by Q2 2030. Data will be accessible to qualified investigators for biomedical research through the NIDDK Central Repository, with requests managed under a Data Use Agreement. IRB approval or exemption is required, and data may not be used for ancestry or non-biomedical research.
Marco de tiempo para compartir IPD
Start Date:
Individual participant data (IPD) and supporting documents will become available at the time of primary results publication or by the end of the study award period, whichever occurs first. Availability is expected to begin by Q2 2030.
End Date:
IPD will remain available indefinitely through the NIDDK Central Repository, as long as the repository remains active and able to distribute the data under its Data Use Agreement procedures.
Criterios de acceso compartido de IPD
Individual participant data (IPD) and supporting materials will be available to qualified investigators conducting health-related, medical, or biomedical research. Requestors must submit a research proposal and obtain institutional IRB approval or exemption before access is granted.
Data will be shared in de-identified form through the NIDDK Central Repository, which manages requests under its governed Data Use Agreement (DUA) process. Approved investigators will be able to access the de-identified IPD, study protocol, and data dictionary through the repository's secure system. No identifiable information or genetic data will be shared.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
- CÓDIGO_ANALÍTICO
- RSC
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .